Merck Biopharma Korea said that GC would market Glucophage, its diabetes treatment, in Korea from next year.
|Merck Biopharma's diabetes treatment Glucophage|
Under the accord, GC will be responsible for marketing activities, such as promoting the product to medical workers and managing sales personnel management, while Merck BioPharma Korea maintains the permit for the product.
Glucophage is the world's first metformin preparation introduced by Merck in France in 1959. The drug is the first-line treatment for diabetes in all international treatment guidelines and is the most prescribed oral antidiabetic drug in the world. Merck uses its manufacturing infrastructure to produce Glucophage.
"The agreement is part of Merck's global healthcare corporate strategy to become a specialty innovator as it focuses its capabilities on specialty care through innovative products in the future," Merck Biopharma Korea said.
Merck plans to focus on its specialty care products, including immunotherapy Bavencio, multiple sclerosis drug Mavenclad, and infertility medicine Pergoveris, it added.
"Based on our company’s philosophy 'As one for Patients,' we are focusing on helping patients in Korea by making the most of our best therapies in oncology, infertility, and neurology," Merck Biopharma Korea General Manager Javad Alam said. "We are confident that the deal with GC, which has a strong and broad sales network, will allow Glucophage to reach more diabetes patients."
<© Korea Biomedical Review, All rights reserved.>